Jawahar Tummala, MD
Adolescent Medicine · Flint, MINPI 1225006745
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations. Among adolescent medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$254
- Neurelis, Inc.$233
- Neurocrine Biosciences, Inc.$158
- Biogen$147
- Alnylam Pharmaceuticals Inc.$132
- AbbVie$118
- plus $1K from 35 others
What the payments were for
- Food & beverage$2,481100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 11 | $254 |
| Neurelis, Inc. | 9 | $233 |
| Neurocrine Biosciences, Inc. | 5 | $158 |
| Biogen | 7 | $147 |
| Alnylam Pharmaceuticals Inc. | 6 | $132 |
| AbbVie | 5 | $118 |
| Aquestive Therapeutics, Inc. | 7 | $109 |
| Jazz Pharmaceuticals Inc. | 4 | $94 |
| Medtronic | 1 | $92 |
| Lilly USA, LLC | 5 | $85 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| Bristol Myers Squibb | 4 | $76 |
| Sanofi | 3 | $67 |
| Catalyst Pharmaceuticals, Inc. | 3 | $61 |
| Acadia Pharmaceuticals Inc | 2 | $56 |
| Abbott | 1 | $51 |
| Genentech USA, Inc. | 3 | $51 |
| Johnson & Johnson | 3 | $48 |
| Lundbeck LLC | 2 | $46 |
| Aucta Pharmaceuticals, Inc. | 2 | $43 |
| Amgen | 2 | $37 |
| AstraZeneca(2 entities) | 2 | $33 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Tersera Therapeutics LLC | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| GRT US Holding, Inc. | 2 | $27 |
| Corium, LLC | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $23 |
| Pfizer | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Argenx US, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Avion Pharmaceuticals | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Novartis | 1 | $14 |
| Octapharma USA, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
How this compares
$2,481 in reported general payments places this provider in the 90th percentile of 70 adolescent medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $15,529 |
| Atorvastatin Calcium | 85 | $1,559 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 28 | $990 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 22 | $868 |
| Metoprolol Succinate | 37 | $726 |
| Glipizide ErGlipizide | 30 | $675 |
| Pantoprazole Sodium | 17 | $463 |
| Levothyroxine Sodium | 32 | $346 |
| Carvedilol | 25 | $292 |
| Atenolol | 18 | $274 |
| Allopurinol | 21 | $245 |
| Diclofenac Sodium | 11 | $228 |
| Amlodipine Besylate | 27 | $208 |
| Metoprolol Tartrate | 23 | $208 |
| Meloxicam | 28 | $192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $34632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 70 adolescent medicine providers in Michigan.
Other adolescent medicine in Flint
- Bishoy ElbebawyFlint$18K
- Sasikala VemuriFlint$1K
- Lisa LoweryGrand Rapids$12K
- Gursharn DosanjhGrandville$5K
- Erica HardingClarkston$5K
- Antoun OskaWarren$3K
- Ashraf BerryWarren$3K
- Nahid ElyasFarmington Hills$2K
- Husain ArastuWarren$2K
- Robert LevyDearborn$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.